期刊文献+

辅助内分泌治疗对乳腺癌术后患者血脂水平的影响 被引量:6

下载PDF
导出
摘要 目的:观察乳腺癌患者术后辅助内分泌治疗血脂水平的变化。方法:2006年1月至2008年12月期间,对92例乳腺癌患者术后实行辅助内分泌治疗,动态抽血测定其甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL)、低密度脂蛋白胆固醇(LDL)等参数的变化。结果:经过2年的辅助内分泌治疗后,TG由(1.43±1.24)mmol/L上升至(1.92±1.17)mmol/L,差异有统计学意义;尤其在血脂正常或50岁以下患者,内分泌治疗后TG分别由(1.07±0.70)mmol/L和(1.04±0.49)mmol/L上升至(1.76±0.99)mmol/L和(1.72±0.67)mmol/L,差异有统计学意义。结论:乳腺癌术后辅助内分泌治疗,可导致其TG的升高,特别对于血脂正常及50岁以下的患者影响更为明显。长期辅助内分泌治疗的患者应加强血脂水平的检测,以减轻潜在心血管疾病的发生。
出处 《实用医学杂志》 CAS 北大核心 2011年第16期2995-2998,共4页 The Journal of Practical Medicine
  • 相关文献

参考文献14

  • 1陈登峰.多西他赛联合表柔比星在局部晚期乳腺癌新辅助化疗中的疗效[J].实用医学杂志,2010,26(22):4194-4196. 被引量:11
  • 2陈馨,王雪晨,袁毅路,姚永忠,桑剑峰,苏磊.新辅助化疗TT_(hp)C方案在局部晚期乳腺癌患者中的应用效果分析[J].实用医学杂志,2010,26(15):2798-2800. 被引量:5
  • 3Lewis S. Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women [J]. Am Heart J, 2007,153 (2): 182-188.
  • 4王东民.2009年圣·安东尼奥乳腺癌研讨会内分泌治疗热点报道[J].中华乳腺病杂志(电子版),2010,4(2):27-29. 被引量:5
  • 5Buzdar A,Howell A, Cuzick J, et al. Comprehensive side- effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial [J]. Lancet Oneol, 2006,7(8) :633-43.
  • 6Liu C L, Yang T L. Sequential changes in serum triglyceride levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction [J]. Breast Cancer Res Treat, 2003,79 ( 1 ) : 11-16.
  • 7Hozumi Y, Kawano M, Saito T, et al.Effect of tamoxifen on serum lipid metabolism [J]. J Clin Endocrinol Metab, 1998, 83(5) : 1633-1535.
  • 8Kataja V, Hietanen P, Joensuu H, et al. The effects of adjuvant anastrozole, exemestane, tamoxifen, and toremifene on serum lipids in postmenopansal women with breast cancer-a randomized study [J]. Breast Cancer Res Treat, 2002,76(Suppl 1 ) : S156.
  • 9Erkkola R, Mattila L, Powles T, et al.Bone mineral density and lipid changes during 5 years of follow-up in a study of prevention of breast cancer with toremifene in healthy, high- risk pre-and post-menopansal women [J]. Breast Cancer Res Treat, 2005,93(3) :277-287.
  • 10Wasan K M, Goss P E, Pritchard P H, et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L) [J]. Ann Oncol, 2005, 16(5) :707-715.

二级参考文献15

  • 1刘芳,江泽飞,宋三泰,刘晓晴,王涛,闫敏,张少华,郝春芳,孙君重,申戈.单药紫杉醇治疗晚期乳腺癌剂量强度与疗效和毒性的关系[J].中华肿瘤杂志,2005,27(1):56-58. 被引量:36
  • 2江歌丽,杨家祥,朱宁生,刘晓渝,向前.多烯紫杉醇单药治疗晚期乳腺癌的临床研究[J].重庆医学,2005,34(12):1791-1791. 被引量:8
  • 3王雪晨,姚永忠,钱晓萍,刘宝瑞.新辅助化疗对乳腺癌骨髓微转移的影响[J].江苏医药,2006,32(2):134-135. 被引量:10
  • 4魏爱英,张庆柱,张捷.多西他赛诱导乳腺癌Bcap37细胞凋亡作用的研究[J].中华肿瘤防治杂志,2006,13(18):1384-1386. 被引量:10
  • 5Cady B.Breast cancer in the third millennium[J].J Surg Oncol,2001,77(4):225-232.
  • 6Lara F,Delagarza J,Bamirez T,et al.High pathological complete response(PCR)afar neoadjuvant chemotherapy with doxoruhicin and docetaxel in locally advanced breast cancer[J].Proc Am Soc Clin Oncol,2000(19):126a.
  • 7Henderson I C,Berry D,Demetri G D,et al.Improved outcomes from adding sequential paclitaxel but not from eslating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node positive primary breast cancer[J].J Clin Oncol,2003,21(6):976-983.
  • 8Shimizu T.Weekly administration of paclitaxel and pirarubicine for recurrent breast cancer[J].Gan To Kagaku Ryoho,2003,30(1):105-109.
  • 9Garces C A,Cance W G.Neoadjuvant chemotherapy of breast cancer[J].Am Surg,2004,70(7):565-569.
  • 10Hutcheon A W,Ogston K N,Heys S D,et al.Primary chemotherapy in the treatment of breast cancer:significantly enhanced clinical and pathological response with docetaxel[J].Proc Am Soc Clin Oncol,2000(19):83.

共引文献16

同被引文献101

  • 1田丽军,徐兵河.托瑞米芬和他莫昔芬对血脂影响的对比研究[J].实用癌症杂志,2004,19(5):520-522. 被引量:7
  • 2Janni W,Hepp P. Adjuvant aromatase inhibitor therapy:Outcomes and safety[J].Cancer Treatment Reviews,2010,(03):249-261.
  • 3Chang N W,Chen F N,Wu C T. Apolipoprotein E4allele influences the response of plasma triglyceride levels to tamoxifen in breast cancer patients[J].Clinica Chimica Acta,2009,(1-2):144-147.
  • 4Lewis S. Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women[J].American Heart Journal,2007,(02):182-188.
  • 5Lewis J D,Chagpar A B,Shaughnessy E A. Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer[J].Cancer,2010,(10):2307-2315.
  • 6Tominaga T,Kimijima I,Kimura M. Effect of toremifen and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer:interim from a Japanese phase Ⅲ trial[J].Jpan J Clin,2010,(07):627-633.
  • 7Hozumi Y,Suemasu K,Takei H. The effect of exemestane,anastrozole,and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients:final results of National surgical adjuvant studay BC 04,the TEAM Japan sub-study[J].Annals of Oncology,2011,(08):1777-1782.
  • 8Nordenskjold B,Rosell J,Rutqvist L E. Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy:results from a randomized trial[J].J Natl Cancer,2005,(21):1609-1610.
  • 9Wojtacki J,Lesniewski-Kmak K,Pawlak W. Anastrozole therapy and lipid profile:an update[J].European Journal of Cancer,2004,(Suppl 2):142.
  • 10Anan K,Mitsnyama S,Yanagita Y. Effects of toremifene and anastrozole on serum lipids and bone metabolism in postmenopausal females with estrogen receptor-pesitive breast cancer:the results of a 2-year muhicenter open randomized study[J].Breast Cancer Research and Treatment,2011,(03):775-781.

引证文献6

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部